Pfizer’s Ibrance is set to lose exclusivity in the US only by 2027, but the Indian market is buzzing with activity as generics including from top-ranked drug maker Sun Pharma vie for a share of the pie. Competing CDK4/6 inhibitors are already available but can cut-price palbociclib versions alter market dynamics?
2023 has brought with it some big-ticket patent expiries on the Indian market.
Even as twists and turns around the patent battle pertaining to Novartis AG’s heart-failure therapy Entresto (sacubitril/valsartan) continue to play out, frontline Indian companies have hit the market with...